Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Guideline-recommended medications: variation across Medicare Advantage plans and associated mortality.

Selim AJ, Fincke BG, Rogers WH, Qian S, Selim BJ, Kazis LE.

J Manag Care Pharm. 2013 Mar;19(2):132-8.

2.

Use of guideline-recommended therapies for heart failure in the Medicare population.

DiMartino LD, Shea AM, Hernandez AF, Curtis LH.

Clin Cardiol. 2010 Jul;33(7):400-5. doi: 10.1002/clc.20760.

3.

Practice-level variation in use of recommended medications among outpatients with heart failure: Insights from the NCDR PINNACLE program.

Peterson PN, Chan PS, Spertus JA, Tang F, Jones PG, Ezekowitz JA, Allen LA, Masoudi FA, Maddox TM.

Circ Heart Fail. 2013 Nov;6(6):1132-8. doi: 10.1161/CIRCHEARTFAILURE.113.000163. Epub 2013 Oct 15.

4.

How does drug treatment for diabetes compare between Medicare Advantage prescription drug plans (MAPDs) and stand-alone prescription drug plans (PDPs)?

Erten MZ, Stuart B, Davidoff AJ, Shoemaker JS, Bryant-Comstock L, Shenolikar R.

Health Serv Res. 2013 Jun;48(3):1057-75. doi: 10.1111/1475-6773.12016. Epub 2012 Dec 3.

5.

Prescription drug benefits and use of guideline recommended medications by elderly Medicare beneficiaries with diabetes mellitus.

Tjia J, Briesacher BA.

J Am Geriatr Soc. 2008 Oct;56(10):1879-86. doi: 10.1111/j.1532-5415.2008.01917.x. Epub 2008 Sep 2.

7.

Neither diabetes nor glucose-lowering drugs are associated with mortality after noncardiac surgery in patients with coronary artery disease or heart failure.

Hanninen M, McAlister FA, Bakal JA, van Diepen S, Ezekowitz JA.

Can J Cardiol. 2013 Apr;29(4):423-8. doi: 10.1016/j.cjca.2012.07.004. Epub 2012 Sep 15.

PMID:
22985785
8.

Quality of medical management in coronary artery disease.

Al Shammeri O, Stafford RS, Alzenaidi A, Al-Hutaly B, Abdulmonem A.

Ann Saudi Med. 2014 Nov-Dec;34(6):488-93. doi: 10.5144/0256-4947.2014.488.

PMID:
25971821
9.

Appropriateness of Prescriptions of Recommended Treatments in Organisation for Economic Co-operation and Development Health Systems: Findings Based on the Long-Term Registry of the European Society of Cardiology on Heart Failure.

Maggioni AP, Van Gool K, Biondi N, Urso R, Klazinga N, Ferrari R, Maniadakis N, Tavazzi L.

Value Health. 2015 Dec;18(8):1098-104. doi: 10.1016/j.jval.2015.08.005. Epub 2015 Sep 14.

PMID:
26686796
10.

Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling.

Güder G, Störk S, Gelbrich G, Brenner S, Deubner N, Morbach C, Wallenborn J, Berliner D, Ertl G, Angermann CE.

Eur J Heart Fail. 2015 Apr;17(4):442-52. doi: 10.1002/ejhf.252. Epub 2015 Mar 2.

11.

Association between process quality measures for heart failure and mortality among US veterans.

Wu WC, Jiang L, Friedmann PD, Trivedi A.

Am Heart J. 2014 Nov;168(5):713-20. doi: 10.1016/j.ahj.2014.06.024. Epub 2014 Jul 11.

PMID:
25440800
12.

Reasons for not prescribing guideline-recommended medications to adults with heart failure.

Steinman MA, Dimaano L, Peterson CA, Heidenreich PA, Knight SJ, Fung KZ, Kaboli PJ.

Med Care. 2013 Oct;51(10):901-7. doi: 10.1097/MLR.0b013e3182a3e525.

13.

Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.

Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J.

Am J Kidney Dis. 2005 Dec;46(6):1080-7.

PMID:
16310574
14.

[A study of the influence of the guideline on the treatment of chronic congestive heart failure in the elderly].

Liu J, Ma JP, Huang JH, Wang L.

Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2010 Oct;22(10):606-9. Chinese.

15.

Utilisation of medications recommended for chronic heart failure and the relationship with annual hospitalisation duration in patients over 75 years of age. A pharmacoepidemiological study.

Maison P, Cunin P, Hemery F, Fric F, Elie N, Del'volgo A, Dubois-Randé JL, Hittinger L, Macquin-Mavier I.

Eur J Clin Pharmacol. 2005 Jul;61(5-6):445-51. Epub 2005 Jun 7.

PMID:
15940531
16.

Association between performance measures and clinical outcomes for patients hospitalized with heart failure.

Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Pieper K, Sun JL, Yancy C, Young JB; OPTIMIZE-HF Investigators and Hospitals.

JAMA. 2007 Jan 3;297(1):61-70.

PMID:
17200476
17.

Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfil guideline recommended targets? A report from the EUROASPIRE III cross-sectional study.

Gyberg V, Kotseva K, Dallongeville J, Backer GD, Mellbin L, Rydén L, Wood D, Bacquer DD; EUROASPIRE Study Group.

Eur J Prev Cardiol. 2015 Jun;22(6):753-61. doi: 10.1177/2047487314529353. Epub 2014 Apr 1.

PMID:
24691153
18.

Pharmacologic treatment in dialysis patients hospitalized for cardiovascular reasons: do we follow the guidelines?

Tomaszuk-Kazberuk A, Kozuch M, Malyszko J, Bachorzewska-Gajewska H, Dobrzycki S, Musial WJ.

Ren Fail. 2013;35(2):235-42. doi: 10.3109/0886022X.2012.745119. Epub 2012 Nov 26.

PMID:
23176538
19.
20.

Comparison of statin adherence among beneficiaries in MA-PD plans versus PDPs.

Jung K, McBean AM, Kim JA.

J Manag Care Pharm. 2012 Mar;18(2):106-15.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk